NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Individuals Who Provided Content Development and/or Authorship Assistance

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Mary A. Dwyer, MS, CGC, Director, Guidelines Operations, NCCN
Hema Sundar, PhD, Manager, Global Clinical Content, NCCN

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
William G. Wierda, MD, PhD, Panel Chair, grant/research support from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Cyclacel Pharmaceuticals, Inc., Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceutica Products, LP, Juno Therapeutics, Inc., Kite Pharma, Miragen Therapeutics, Inc., Oncternal Therapeutics, Inc., Pharmacyclics, Sunesis Pharmaceuticals, Inc., and Xencor, Inc.
Jennifer Brown, MD, PhD, Panel Vice Chair, consulting fees from AbbVie, Inc./Roche Laboratories, Inc., Acerta Pharma/AstraZeneca Pharmaceuticals LP, BeiGene/AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company/Celgene Corporation/Juno Therapeutics, Catapult Therapeutics, Eli Lilly and Company, Genentech, Inc./Roche Laboratories, Inc., Janssen Pharmaceutica, Products, LP., MEI Pharma Inc., MorphoSys AG, Nextcea, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Rigel Pharmaceuticals, Inc.; grant/research support from Gilead Sciences Inc., Loxo Oncology at Lilly, Secura Bio, Inc., Sun Pharma, and TG Therapeutics, Inc.; and scientific advisor for Invectys.

View all of the conflicts of interest for the NCCN Guidelines panel

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.